Wall Street Zen Downgrades Establishment Labs (NASDAQ:ESTA) to Sell

Establishment Labs (NASDAQ:ESTA - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Thursday.

Several other brokerages also recently issued reports on ESTA. Stephens reissued an "overweight" rating and issued a $52.00 price target on shares of Establishment Labs in a report on Thursday, March 6th. Needham & Company LLC raised Establishment Labs from a "hold" rating to a "buy" rating and set a $48.00 price target on the stock in a report on Wednesday, May 14th. Finally, BTIG Research began coverage on Establishment Labs in a report on Friday, May 16th. They issued a "buy" rating and a $62.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Establishment Labs presently has an average rating of "Moderate Buy" and an average target price of $55.33.

Establishment Labs Stock Performance

NASDAQ:ESTA traded down $0.23 during trading hours on Thursday, reaching $36.62. 306,871 shares of the stock were exchanged, compared to its average volume of 473,448. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. The firm has a 50 day simple moving average of $34.33 and a 200-day simple moving average of $37.88. Establishment Labs has a 52 week low of $26.56 and a 52 week high of $58.00. The stock has a market capitalization of $1.06 billion, a P/E ratio of -14.19 and a beta of 0.73.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.13. The business had revenue of $41.38 million for the quarter, compared to the consensus estimate of $41.15 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The business's revenue was up 11.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.58) EPS. As a group, sell-side analysts forecast that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Institutional Trading of Establishment Labs

Several large investors have recently added to or reduced their stakes in the business. Brown Advisory Inc. increased its position in Establishment Labs by 23.1% in the 4th quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company's stock valued at $107,729,000 after acquiring an additional 438,057 shares during the period. Capital Research Global Investors increased its position in Establishment Labs by 29.3% in the 4th quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock valued at $88,064,000 after acquiring an additional 433,484 shares during the period. Nantahala Capital Management LLC increased its position in Establishment Labs by 7.2% in the 1st quarter. Nantahala Capital Management LLC now owns 1,774,044 shares of the company's stock valued at $72,390,000 after acquiring an additional 119,574 shares during the period. Findell Capital Management LLC increased its position in shares of Establishment Labs by 28.5% during the 4th quarter. Findell Capital Management LLC now owns 1,346,480 shares of the company's stock valued at $62,032,000 after purchasing an additional 298,380 shares during the period. Finally, Rice Hall James & Associates LLC increased its position in shares of Establishment Labs by 7.4% during the 1st quarter. Rice Hall James & Associates LLC now owns 827,423 shares of the company's stock valued at $33,763,000 after purchasing an additional 56,756 shares during the period. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.